Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS) (NCT06675864)
An Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression, and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
🩺 Plain-English Summary (8th-Grade Level)
This is an open-label, multi-center, non-confirmatory study to assess the safety, disease progression, and cellular kinetics following YTB323 administration to 28 participants with non-active Progressive Multiple Sclerosis (PMS). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort.
Who can join: Review the eligibility criteria below.
Location: Novartis Investigative Site — Darlinghurst, New South Wales
Age range: 18 Years to 60 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- Novartis Investigative Site — Darlinghurst, New South Wales
- Novartis Investigative Site — Melbourne, Victoria
- Novartis Investigative Site — Québec, Quebec
- Novartis Investigative Site — Bron,
- Novartis Investigative Site — Montpellier,
- Novartis Investigative Site — Nancy,
- Novartis Investigative Site — Rennes,
- Novartis Investigative Site — Essen,
- Novartis Investigative Site — Mainz,
- Novartis Investigative Site — Ulm,
- Novartis Investigative Site — Genova, GE
- Novartis Investigative Site — Milan, MI
- Novartis Investigative Site — Barcelona,
- Novartis Investigative Site — Madrid,
- Novartis Investigative Site — Málaga,
- Novartis Investigative Site — Bern,
- Novartis Investigative Site — Lausanne,
- Novartis Investigative Site — Zurich,
📞 Contact the Study Coordinator
Phone: +41613241111
Email: novartis.email@novartis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
- 💵 Compensation indicated: Different groups of participants may receive a higher dose of YTB323, if proven to be safe for every participant at the lower dose.
More studies in Progressive Multiple Sclerosis
- Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients — Ann Arbor, Michigan
- A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis — San Francisco, California
- Obe-cel in Refractory Progressive Forms of Multiple Sclerosis — Redwood City, California
- ABA-101 in Participants With Progressive Multiple Sclerosis — Baltimore, Maryland
Explore by condition: All Progressive Multiple Sclerosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.